Research Paper Volume 7, Issue 11 pp 956—963
Association analysis of insulin-like growth factor-1 axis parameters with survival and functional status in nonagenarians of the Leiden Longevity Study
- 1 Department of Gerontology and Geriatrics, Leiden University Medical Center, The Netherlands
- 2 Netherlands Consortium of Healthy Aging (NCHA), The Netherlands
- 3 Department of Medical Statistics, Leiden University Medical Center, The Netherlands
- 4 Section Molecular Epidemiology, Leiden University Medical Center, The Netherlands
- 5 Department of Public Health, University of Copenhagen, Denmark
Received: September 4, 2015 Accepted: November 2, 2015 Published: November 12, 2015
https://doi.org/10.18632/aging.100841How to Cite
Abstract
Reduced insulin/insulin-like growth factor 1 (IGF-1) signaling has been associated with longevity in various model organisms. However, the role of insulin/IGF-1 signaling in human survival remains controversial. The aim of this study was to test whether circulating IGF-1 axis parameters associate with old age survival and functional status in nonagenarians from the Leiden Longevity Study. This study examined 858 Dutch nonagenarian (males≥89 years; females≥91 years) siblings from 409 families, without selection on health or demographic characteristics. Nonagenarians were divided over sex-specific strata according to their levels of IGF-1, IGF binding protein 3 and IGF-1/IGFBP3 molar ratio. We found that lower IGF-1/IGFBP3 ratios were associated with improved survival: nonagenarians in the quartile of the lowest ratio had a lower estimated hazard ratio (95% confidence interval) of 0.73 (0.59 – 0.91) compared to the quartile with the highest ratio (ptrend=0.002). Functional status was assessed by (Instrumental) Activities of Daily Living ((I)ADL) scales. Compared to those in the quartile with the highest IGF-1/IGFBP3 ratio, nonagenarians in the lowest quartile had higher scores for ADL (ptrend=0.001) and IADL (ptrend=0.003). These findings suggest that IGF-1 axis parameters are associated with increased old age survival and better functional status in nonagenarians from the Leiden Longevity Study.
Introduction
The role of the evolutionarily conserved insulin/insulin-like growth factor (IGF-1) signaling (IIS) pathway in the regulation of lifespan is well documented in worms [1], flies [2], and rodents [3,4]. Genetic mutations that inhibit IIS activation prolong lifespan in these organisms, particularly in the female sex. The involvement of IIS modulation in human longevity is less clear [5]. In agreement with the findings in model organisms, reduced IIS pathway activity was associated with old age survival in sporadic female octogenarians and different cohorts of nonagenarians [6,7] as well as with better cognitive function [8]. Furthermore, centenarians were shown to be enriched for rare IGF-1R mutations associated with IGF-1 resistance [9]. As in mice, mutations causing growth hormone (GH) resistance resulting in low circulating levels of IGF-1 have been reported to confer protection against the development of cancer and diabetes in men [10].
Circulatory IGF-1 is mostly bound to any of six high affinity IGF binding proteins, of which IGF binding protein 3 (IGFBP3) is the most abundant. The IGFBP3 glycoprotein forms a complex with IGF-1 and an acid-labile component and serves as a reservoir of IGF-1 in the circulation. IGF-1 is only biologically active in its free form, which accounts for approximately 1% of total IGF-1. Therefore the IGF-1/IGFBP3 molar ratio is considered a better indicator of IGF-1 bioavailability than total IGF-1. [11,12] Both IGF-1 and IGBP3 are under control of GH [13]. With age, levels of GH decline as do the levels of IGF-1 and IGFBP3 [14]. In contrast to the apparent beneficial effects associated with constitutively low GH/IGF-1 activity discussed above, lower serum IGF-1 levels in humans have also been associated with an increased risk of developing cardiovascular disease and diabetes [15].
In order to identify heritable determinants of longevity we set up the Leiden Longevity Study. This study includes nonagenarian siblings, recruited from 421 Caucasian families based on proband siblings that both exhibit exceptional longevity [16] and their offspring [17]. Using pathway analysis, a significant difference was detected between nonagenarians from the Leiden Longevity Study and a younger age group for the joint effect of genetic variation in the insulin/IGF-1 signaling pathway [18]. In seeming contrast, earlier we reported on the lack of differences in serum levels of IGF-1 axis parameters between middle-aged offspring of familial nonagenarians and controls [19]. However as not all offspring will inherit the favorable genetic predisposition for longevity of their long-lived parent it is unclear to what extent serum levels of IGF-1 axis parameters in middle-aged offspring are reflective of a constitutional phenotype predisposing to longevity. Therefore, in the current study we aim to examine whether circulating levels of IGF-1, IGFBP3 and IGF-1/IGFBP3 molar ratio are associated with old age survival and functional status in nonagenarian siblings from the Leiden Longevity Study.
Results
Baseline characteristics
The baseline features of the study population (n=858) are displayed stratified for women (n=528) and men (n=330) in Table 1. The median age of women (93.6 years) was higher than that of men (91.4 years). Women and men also showed significant differences in circulating levels of IGFBP3 and the IGF-1/IGFPB3 molar ratio as well as in scores for cognition, functional status and circulating levels of free triiodothyronine (Table 1).
Table 1. Baseline characteristics of the study population
| Women | Men | P-value | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants (N) | 528 | 330 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age (years) | 93.6 (92.2 – 95.3) | 91.4 (90.1 – 93.7) | <0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Family mortality history score parents | −1.4 (−2.8 – −0.2) | −1.3 (−2.5 – −0.2) | 0.94 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| IGF-1 (nmol/L) | 10.1 (7.7 – 13.0) | 10.1 (7.6 – 13.2) | 0.98 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| IGFBP3 (mg/L)†* | 3.2 (0.9) | 2.7 (0.8) | <0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| IGF-1/IGFBP3 molar ratio* | 0.09 (0.08 – 0.11) | 0.11 (0.10 – 0.13) | <0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disability (points) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mini-Mental State Examination∼ | 25 (21 - 28) | 26 (24 – 28) | 0.03 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Activities of Daily Living (ADL)# | 17 (13 – 19) | 19 (17 – 20) | <0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Instrumental ADL# | 7 (3 – 11) | 10 (6 – 12) | <0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-fasted glucose• | 6.1 (5.3 - 7.2) | 6.1 (5.4 – 7.1) | 0.81 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-fasted insulin | 21.0 (11.3 – 36.0) | 23.0 (12.0 – 37.0) | 0.39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Free triiodothyronine (pmol/L)† | 4.0 (0.7) | 4.1 (0.7) | 0.04 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| High sensitivity C-reactive protein (mg/L)‡ | 2.7 (1.3 – 5.4) | 3.0 (1.4 – 6.6) | 0.31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Unless specified otherwise, data are presented as median with interquartile ranges and analyzed with a non-parametric Median Test. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| data are presented as mean with standard deviation and analyzed with linear regression. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| data available for 527 women and 329 men; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| data available for 467 women and 308 men; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| data available for 488 women and 307 men; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| data available for 527 women and 327 men; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| data available for 528 women and 329 men | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Association of IGF-1 axis parameters and survival
Nonagenarian siblings were divided over four sex-specific strata according to their circulating levels of IGF-1, IGFBP3 or their IGF-1/IGFBP3 molar ratio. In Table 2, we assessed the relation between quartiles of serum IGF-1 axis parameters and survival, using a left truncated Cox proportional hazards model to correct for the delayed entry into the risk set according to age. Table 2 shows that lower IGF-1/IGFBP3 molar ratios were associated with significantly lower hazard ratios (p for trend = 0.002). There was no interaction between sex-specific quartiles of IGF-1/IGFBP3 molar ratios and sex (p = 0.57). We found a proportional hazard ratio of 0.73 for nonagenarians in the quartile with the lowest IGF-1/IGFBP3 ratio, which is indicative of a 27% higher chance of survival compared to nonagenarians in the quartile with the highest IGF-1/IGFBP3 ratio. Moreover, observed effects did not change during the course of follow-up (data not shown).
Table 2. Estimated hazard ratios for sex-specific quartiles of serum IGF-1 axis parameters
| Median (range) women | Median (range) men | Hazard ratio | P-value | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IGF-1 (nmol/L) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q1 | 6.3 (3.1 – 7.6) | 6.5 (3.6 – 7.5) | 0.89 (0.72 – 1.11) | 0.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q2 | 8.7 (7.7 – 10.0) | 9.0 (7.6 – 10.0) | 0.81 (0.65 – 1.00) | 0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q3 | 11.4 (10.1 – 12.9) | 11.4 (10.1 – 13.0) | 0.94 (0.77 – 1.14) | 0.52 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q4 | 15.8 (13.0 – 31.3) | 15.3 (13.2 – 30.5) | 1 (ref) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P for trend | 0.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| IGFBP3 (mg/L) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q1 | 2.2 (0.8 – 2.5) | 1.8 (1.0 – 2.0) | 1.11 (0.90 – 1.37) | 0.35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q2 | 2.8 (2.6 – 3.0) | 2.3 (2.1 – 2.5) | 1.04 (0.85 – 1.26) | 0.72 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q3 | 3.3 (3.1 – 3.6) | 2.8 (2.6 – 3.0) | 0.99 (0.81 – 1.20) | 0.89 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q4 | 4.2 (3.7 – 6.7) | 3.5 (3.1 – 10.1) | 1 (ref) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P for trend | 0.31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| IGF-1/IGFBP3molar ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q1 | 0.07 (0.05 – 0.08) | 0.09 (0.02 – 0.10) | 0.73 (0.59 – 0.91) | 0.005 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q2 | 0.09 (0.08 – 0.09) | 0.11 (0.10 – 0.11) | 0.74 (0.59 – 0.92) | 0.007 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q3 | 0.10 (0.09 – 0.11) | 0.12 (0.11 – 0.13) | 0.87 (0.72 – 1.06) | 0.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Q4 | 0.13 (0.11 – 0.21) | 0.15 (0.13 – 0.29) | 1 (ref) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P for trend | 0.002 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Data are presented as estimated hazard ratios with 95% confidence intervals per sex-specific quartiles (Q) of IGF-1, IGFBP3 or IGF-1/IGFBP3 molar ratio as compared to highest quartile, analyzed with cox regression adjusted for family relationship. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Association of IGF-1/IGFBP3 molar ratio and functional status
Next we assessed the relation between quartiles of serum IGF-1 axis parameters and available baseline measures of functional status and health. Table 3 shows that lower IGF-1/IGFBP3 molar ratios in nonagenarians were associated with less physical disability. Compared to nonagenarians in the quartile with the highest IGF-1/IGFBP3 ratios, those in the quartile of the lowest IGF-1/IGFBP3 molar ratios had higher mean (95% CI) scores for both Activities of Daily Living (ADL) (16.8 (16.3 – 17.4) vs 15.2 (14.5 – 15.9), p for trend = 0.001) and Instrumental Activities of Daily Living (IADL) (8.0 (7.4 – 8.7) vs 6.9 (6.3 – 7.5), p for trend = 0.003). The Mini-Mental State Examination (MMSE) did not significantly differ across quartiles. Interestingly, lower IGF-1/IGFBP3 molar ratios were associated with lower levels of non-fasted insulin.
Table 3. Baseline characteristics for quartiles of IGF-1/IGFBP3 molar ratio
| Q1 | Q2 | Q3 | Q4 | P for trend | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Demographics | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Participants (N) | 213 | 213 | 215 | 215 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Men (N, %) | 82 (38.5) | 82 (38.5) | 83 (38.6) | 82 (38.1) | 0.95 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age (years) | 93.5 (93.1 – 93.8) | 93.3 (93.0 – 93.7) | 93.4 (93.0 – 93.7) | 93.1 (92.8 – 93.5) | 0.27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disability (points) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mini-Mental State Examination∼ | 24.4 (23.7 – 25.2) | 24.5 (23.7 – 25.2) | 24.5 (23.8 – 25.1) | 23.6 (22.8 – 24.4) | 0.11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Activities of Daily Living (ADL)# | 16.8 (16.3 – 17.4) | 16.4 (15.7 – 17.1) | 16.2 (15.6 – 16.8) | 15.2 (14.5 – 15.9) | 0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Instrumental ADL# | 8.0 (7.4 – 8.7) | 8.2 (7.6 – 8.8) | 7.6 (7.0 – 8.1) | 6.9 (6.3 – 7.5) | 0.003 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Serum parameters | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-fasted glucose• | 6.2 (5.9 – 6.4) | 6.4 (6.2 – 6.6) | 6.4 (6.2 – 6.6) | 6.4 (6.2 – 6.7) | 0.10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-fasted insulin | 16.3 (14.4 – 18.5) | 20.7 (18.5 – 23.2) | 20.9 (18.7 – 23.5) | 23.3 (20.9 – 25.9) | <0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Free triiodothyronine (pmol/L) | 4.0 (3.9 – 4.1) | 4.1 (4.0 – 4.2) | 4.1 (4.0 – 4.2) | 4.1 (4.0 – 4.2) | 0.23 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| High sensitivity C-reactive protein (mg/L)‡ | 2.7 (2.3 – 3.2) | 3.2 (2.7 – 3.8) | 2.6 (2.2 – 3.1) | 3.1 (2.6 – 3.7) | 0.64 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Family mortality history score | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Family mortality history score parents | −1.7 (−1.9 – −1.4) | −1.8 (−2.1 – −1.6) | −1.5 (−1.8 – −1.3) | −1.5 (−1.8 – −1.3) | 0.22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Unless specified otherwise, data are presented as mean with 95% confidence interval, analyzed with linear regression adjusted for age and family relationship except for the variables sex, age and family mortality history score parents). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| data available for 774 participants (197 in Q1, 193 in Q2, 189 in Q3, 195 in Q4); | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| data available for 793 participants (192 in Q1, 196 in Q2, 200 in Q3, 205 in Q4); | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| data available for 852 participants (212 in Q1, 212 in Q2, 213 in Q4); | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| data available for 855 participants (212 in Q1) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Family mortality history score
Previously, we had calculated a family mortality history score describing the mortality of the parents of the nonagenarian siblings [20]. To assess whether a lower IGF-1/IGBP3 molar ratio is a feature of familial longevity, we compared the family mortality history score across quartiles of IGF-1/IGFBP3 molar ratio. Table 3 shows that lower IGF-1/IGFBP3 molar ratios in nonagenarians siblings were not associated with a lower family mortality history score (i.e. lower than expected mortality of the parents of the nonagenarian siblings).
Discussion
This study aimed to explore the association of circulating IGF-1 axis serum parameters with survival and functional status in nonagenarian siblings from the Leiden Longevity Study. First we demonstrated that lower IGF-1/IGFBP3 molar ratios conferred a survival benefit at the age of ninety years or older. Secondly, lower IGF-1/IGFBP3 molar ratios were associated with better functional status at the age of ninety years or older.
Our outcomes support the recent observation that low IGF-1 levels predict survival in exceptionally long-lived humans [21]. Not only do we confirm that lower IGF-1 axis serum parameters are related with survival in the oldest old, but we also demonstrate that lower IGF-1 axis serum parameters are associated with better functional status. A large number of studies have reported an association between reduced IIS activity and longevity in various model organisms as well as in human studies showing life extending effects of reduced IGF-1 signaling [1-4,7]. In these studies lifespan extending effects were mostly confined to females, unlike the results presented here. In contrast with our findings, Paolisso et al. observed higher serum IGF-1/IGFBP3 ratios in healthy centenarians when compared to aged controls [22]. Another study showed a higher prevalence of heterozygous mutations in the IGF-1R in Ashkenazi Jewish centenarians compared to controls with concomitant higher serum IGF-1 levels [9]. Moreover they found a sex-specific increase in serum IGF-1 associated with a smaller stature in female offspring of centenarians, suggesting the involvement of reduced IGF-1R activity in human longevity [9]. Unfortunately, anthropometric data were not available in our current study. Therefore we cannot draw firm conclusions as to how the IGF-1/IGFBP3 ratios correlate with the underlying IGF-1 signaling activity in our study population.
It has been suggested that low levels of IGF-1 and/or reduced IGF-1 bioavailability form part of a survival response that can be constitutively active in long-lived individuals as well as elicited by diverse forms of stress, including metabolic stress, genotoxic stress and inflammation [23]. In hospitalized elderly patients, frailty, impairments and mortality were associated with a distinct biomarker signature that comprised higher levels of inflammatory markers and lower levels of growth factors and anabolic hormones, including IGF-1 and free triiodothyronine [24]. In our study, levels of CRP and free triiodothyronine did not differ across quartiles of the IGF-1/IGFBP3 molar ratios, while functional status was better in the quartile with the lowest IGF-1/IGFBP3 ratio, in line with the observed survival benefit.
A limitation of our study is that information about medical history, medication use and specific causes of death is lacking. Previous research suggested that enhancement of insulin sensitivity was a key mediator of the increased longevity of hypopituitary, GH- resistant, and calorie-restricted animals [25]. Moreover, preserved insulin sensitivity was also shown to be a key phenotype of human longevity, both at middle age [26] and at extremely high ages [27]. Previously, we observed lower fasted levels of glucose and insulin when the offspring of the included nonagenarians were compared to an age-matched control group [28]. It is a limitation of the current study that all blood parameters, including IGF-1, IGFBP3, glucose and insulin were determined in non-fasted samples collected at a random moment of the day and that data on insulin sensitivity and food intake were lacking. Circulatory levels of IGF-1 will decrease while levels of its binding proteins (notably IGFBP1) will increase in response to reductions in food intake, in particular the intake of protein [29]. Nevertheless, our finding that lower IGF-1/IGFBP3 molar ratios were associated with relatively lower circulating levels of insulin is suggestive of better insulin sensitivity and in accordance with other recent human data [30]. IGF-1 has structural and functional homology with insulin, and it has been suggested that insulin resistance might lead to increased IGF-1 bioavailability to compensate for reduced insulin action. Another limitation of our study is its cross sectional design which precludes causal inference of the observed associations.
Because we found that lower IGF-1/IGFBP3 ratios were associated with better old age survival in nonagenarians of the LLS, we assessed whether nonagenarian IGF-1/IGFBP3 ratios were associated with a family mortality history score describing the mortality of the parents of the nonagenarian siblings. Our findings on lack of association between nonagenarian IGF-1/IGFBP3 ratios and family mortality history score are in accordance with the lack of difference in IGF-1 axis parameters, including IGF-1, IGFBP3 and the IGF-1/IGFBP3 molar ratios previously observed between middle-aged offspring of familial nonagenarians and controls. These disparate results suggest that the possible benefits of low IGF-1/IGFBP3 ratios may differ according to age and birth cohorts. One of the possible explanations is that with advancing age, the IGF-1/IGFBP3 ratio changes and that those individuals that adapt to a lower IGF-1/IGFBP3 ratio have a survival advantage in old age. Another possibility is selective survival of participants with constitutively lower IGF-1/IGFBP3 ratios. It is possible that selective advantage of variation in the IIS pathway may only become detectable at advanced ages. In line, the association between FOXO3A and longevity was for example found to be stronger in centenarians than in nonagenarians [31]. In our study, a considerable percentage of included nonagenarians (23.8%) also reached an age of 100 years or more. Amongst others, another possible explanation for these contrasting observations could be differences in imprinting of IGF-1 axis genes, reflecting historical differences in maternal nutrition between generations [32].
In conclusion, we showed that in nonagenarian siblings IGF-1/IGFBP3 molar ratios are associated with better survival and functional status. These preliminary findings support the involvement of IGF-1 signaling in modulating human longevity.
Materials and Methods
In the Leiden Longevity Study, 421 families were recruited consisting of long-lived Caucasian siblings together with their offspring and the partners thereof. For the current study, data on IGF-1 and IGFBP3 levels were available for 858 of the 944 nonagenarian participants from the Leiden Longevity Study. After a median follow-up time of 3.4 years (range 0 – 11.5 years), 797 individuals (92.9%) had died. The Medical Ethical Committee of the Leiden University Medical Center approved the study and informed consent was obtained from all subjects. For details on enrollment please see previous publications [17,19].
All serum measurements were performed with fully automated equipment. For IGF-1, IGFBP3, and insulin the Modular E170 was used, for glucose, high sensitivity C-reactive protein (hsCRP) and free triiodothyronine the Cobas Integra 800 was used, both from Roche, Almere, the Netherlands. The coefficients of variation of these measurements were all below 5%.
Global cognitive function was assessed with the Mini-Mental State Examination (MMSE) and functional status was assessed by Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales as described previously [33]. ADL disability scores range from 0 points (fully dependent in all activities) to 20 points (fully independent in all activities). IADL disability scores range from 0 points (fully dependent in all activities) to 14 points (fully independent in all activities). MMSE scores range from zero points (very severe cognitive impairment) to 30 points (optimal cognitive function).
For each parent we computed the sex and birth cohort cumulative hazards using the life tables of the Dutch population. Note that since both parents are deceased one minus the cumulative hazard equals the martingale residual. The martingale residual is defined as the difference between the event status (0 if alive, 1 if deceased) and the cumulative hazard at the observed age (current age or age at death). The sum of the martingale residuals measures the deviation of survival of the parents with respect to their birth cohort. Therefore negative values indicate excess survival and positive values indicate excess mortality.
Nonagenarians were divided over four sex-specific strata according to their circulating levels of IGF-1, IGFBP3 or their IGF-1/IGFBP3 molar ratio. The association between quartiles of IGF-1 axis parameters and baseline characteristics of nonagenarians was assessed using a linear mixed model corrected for correlation of sibling data using robust standard errors clustered on family number. Distributions of continuous variables were examined for normality and logarithmically transformed when appropriate. Survival analyses were performed with a left truncated Cox proportional hazards model to correct for the delayed entry into the risk set according to age and the model was corrected for correlation of sibling data using robust standard errors clustered on family number. The Statistical Package STATA (“statistics and data”) for Windows, version 12.0 SE, and the Statistical Package for the Social Sciences (SPSS) for Windows, version 20.0, were used for data analysis.
Acknowledgments
We thank all participants of the Leiden Longevity Study for their consistent cooperation, as well all participating general practitioners and pharmacists, the secretary staff (Meriam H van der Star and Ellen H Bemer-Oorschot), the research nurse (Corrie J Groenendijk) for their valuable contribution.
Funding
This work was supported by the Innovation Oriented research Program on Genomics (SenterNovem; IGE01014 and IGE5007); the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NGI/NWO; 05040202 and 050-060-810, NCHA) and by the European Community within the Seventh Framework Program under grant agreement no. Health-F2-2010-259772 (Switchbox).
Conflicts of Interest
The authors of this manuscript have no conflict of interests to declare.
References
- 1. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature. 1993; 366:461-464. [PubMed]
- 2. Tatar M, Kopelman A, Epstein D, Tu MP, Yin CM, Garofalo RS. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science. 2001; 292:107-10. [PubMed]
- 3. Brown-Borg HM, Borg KE, Meliska CJ, Bartke A. Dwarf mice and the ageing process. Nature. 1996; 384:33 [PubMed]
- 4. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le BY. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003; 421:182-187. [PubMed]
- 5. van Heemst D. Insulin, IGF-1 and longevity. Aging and Disease. 2010; 1:147-157. [PubMed]
- 6. Pawlikowska L, Hu D, Huntsman S, Sung A, Chu C, Chen J, Joyner AH, Schork NJ, Hsueh WC, Reiner AP, Psaty BM, Atzmon G, Barzilai N, et al. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell. 2009; 8:460-472. [PubMed]
- 7. van Heemst D, Beekman M, Mooijaart SP, Heijmans BT, Brandt BW, Zwaan BJ, Slagboom PE, Westendorp RG. Reduced insulin/IGF-1 signalling and human longevity. Aging Cell. 2005; 4:79-85. [PubMed]
- 8. Euser SM, van Heemst D, van Wet P, Breteler MMB, Westendorp RGJ. Insulin/Insulin-Like Growth Factor-1 Signaling and Cognitive Function in Humans. Journals of Gerontology Series A-Biological Sciences and Medical Sciences. 2008; 63:907-910..
- 9. Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai I, Cohen P. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:3438-442. [PubMed]
- 10. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD. Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans. Science Translational Medicine. 2011; 3:.
- 11. Juul A, Flyvbjerg A, Frystyk J, Muller J, Skakkebaek NE. Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins-1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty. Clinical Endocrinology. 1996; 44:515-523. [PubMed]
- 12. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. Journal of the National Cancer Institute. 2002; 94:972-980. [PubMed]
- 13. Hintz RL, Liu F, Rosenfeld RG, Kemp SF. Plasma Somatomedin-Binding Proteins in Hypopituitarism - Changes During Growth-Hormone Therapy. Journal of Clinical Endocrinology & Metabolism. 1981; 53:100-104. [PubMed]
- 14. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Muller J, Skakkebaek NE. Serum Levels of Insulin-Like Growth-Factor (Igf)-Binding Protein-3 (Igfbp-3) in Healthy Infants, Children, and Adolescents - the Relation to Igf-I, Igf-Ii, Igfbp-1, Igfbp-2, Age, Sex, Body-Mass Index, and Pubertal Maturation. Journal of Clinical Endocrinology & Metabolism. 1995; 80:2534-2542. [PubMed]
- 15. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res. 2003; 13:113-170. [PubMed]
- 16. Schoenmaker M, de Craen AJ, de Meijer PH, Beekman M, Blauw GJ, Slagboom PE, Westendorp RG. Evidence of genetic enrichment for exceptional survival using a family approach: the Leiden Longevity Study. Eur J Hum Genet. 2006; 14:79-84. [PubMed]
- 17. Westendorp RG, van Heemst D, Rozing MP, Frolich M, Mooijaart SP, Blauw GJ, Beekman M, Heijmans BT, de Craen AJ, Slagboom PE. Nonagenarian siblings and their offspring display lower risk of mortality and morbidity than sporadic nonagenarians: The Leiden Longevity Study. J Am Geriatr Soc. 2009; 57:1634-1637. [PubMed]
- 18. Deelen J, Uh HW, Monajemi R, van Heemst D, Thijssen PE, Bohringer S, van den Akker EB, de Craen AJM, Rivadeneira F, Uitterlinden AG, Westendorp RGJ, Goeman JJ, Slagboom PE, et al. Gene set analysis of GWAS data for human longevity highlights the relevance of the insulin/IGF-1 signaling and telomere maintenance pathways. Age. 2013; 35:235-249. [PubMed]
- 19. Rozing MP, Westendorp RG, Frolich M, de Craen AJ, Beekman M, Heijmans BT, Mooijaart SP, Blauw GJ, Slagboom PE, van Heemst D. Human insulin/IGF-1 and familial longevity at middle age. Aging (Albany NY). 2009; 1:714-722. [PubMed]
- 20. Houwing-Duistermaat JJ, Callegaro A, Beekman M, Westendorp RG, Slagboom PE, van Houwelingen JC. Weighted statistics for aggregation and linkage analysis of human longevity in selected families: The Leiden Longevity Study. Statistics in Medicine. 2009; 28:140-151. [PubMed]
- 21. Milman S, Atzmon G, Huffman DM, Wan JX, Crandall JP, Cohen P, Barzilai N. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell. 2014; 13:769-771. [PubMed]
- 22. Paolisso G, Ammendola S, DelBuono A, Gambardella A, Riondino M, Tagliamonte MR, Rizzo MR, Carella C, Varricchio M. Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centenarians: Relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function. Journal of Clinical Endocrinology & Metabolism. 1997; 82:2204-2209. [PubMed]
- 23. Garinis GA, van der Horst GTJ, Vijg J, Hoeijmakers JHJ. DNA damage and ageing: new-age ideas for an age-old problem. Nature Cell Biology. 2008; 10:1241-1247. [PubMed]
- 24. Fontana L, Addante F, Copetti M, Paroni G, Fontana A, Sancarlo D, Pellegrini F, Ferrucci L, Pilotto A. Identification of a metabolic signature for multidimensional impairment and mortality risk in hospitalized older patients. Aging Cell. 2013; 12:459-466. [PubMed]
- 25. Masternak MM, Panici JA, Bonkowski MS, Hughes LF, Bartke A. Insulin Sensitivity as a Key Mediator of Growth Hormone Actions on Longevity. Journals of Gerontology Series A-Biological Sciences and Medical Sciences. 2009; 64:516-521..
- 26. Wijsman CA, Rozing MP, Streefland TCM, le Cessie S, Mooijaart SP, Slagboom PE, Westendorp RGJ, Pijl H, van Heemst D. Familial longevity is marked by enhanced insulin sensitivity. Aging Cell. 2011; 10:114-121. [PubMed]
- 27. Paolisso G, Gambardella A, Ammendola S, DAmore A, Balbi V, Varricchio M, DOnofrio F. Glucose tolerance and insulin action in healthy centenarians. American Journal of Physiology-Endocrinology and Metabolism. 1996; 270:E890-E894..
- 28. Rozing MP, Westendorp RGJ, de Craen AJM, Frolich M, de Goeij MCM, Heijmans BT, Beekman M, Wijsman CA, Mooijaart SP, Blauw GJ, Slagboom PE, van Heemst D. Favorable Glucose Tolerance and Lower Prevalence of Metabolic Syndrome in Offspring without Diabetes Mellitus of Nonagenarian Siblings: The Leiden Longevity Study. Journal of the American Geriatrics Society. 2010; 58:564-569. [PubMed]
- 29. Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, Fontana L, Mirisola MG, Guevara-Aguirre J, Wan J, Passarino G, Kennedy BK, Wei M, et al. Low Protein Intake Is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population. Cell Metabolism. 2014; 19:407-417. [PubMed]
- 30. Aneke-Nash CS, Parrinello CM, Rajpathak SN, Rohan TE, Strotmeyer ES, Kritchevsky SB, Psaty BM, Buzkova P, Kizer JR, Newman AB, Strickler HD, Kaplan RC. Changes in Insulin-Like Growth Factor-I and Its Binding Proteins Are Associated with Diabetes Mellitus in Older Adults. Journal of the American Geriatrics Society. 2015; 63:902-909. [PubMed]
- 31. Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller-Eberstein H, Nikolaus S, Schreiber S, Nebel A. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci U S A. 2009; 106:2700-2705. [PubMed]
- 32. Drake NM, Park YJ, Shirali AS, Cleland TA, Soloway PD. Imprint switch mutations at Rasgrf1 support conflict hypothesis of imprinting and define a growth control mechanism upstream of IGF1. Mammalian Genome. 2009; 20:654-663. [PubMed]
- 33. Bootsma-van der Wiel A, Gussekloo J, de Craen AJM, van Exel E, Knook DL, Lagaay AM, Westendorp RGJ. Disability in the oldest old: “Can do” or “do do”? Journal of the American Geriatrics Society. 2001; 49:909-914. [PubMed]